A dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, attenuates cardiac dysfunction after myocardial infarction independently of DPP-4

• Main Authors: Takehiro Yamaguchi (Author), Ayano Watanabe (Author), Masako Tanaka (Author), Masayuki Shiota (Author), Mayuko Osada-Oka (Author), Soichi Sano (Author), Minoru Yoshiyama (Author), Katsuyuki Miura (Author), Shojiro Kitajima (Author), Shinji Matsunaga (Author), Shuhei Tomita (Author), Hiroshi Iwao (Author), Yasukatsu Izumi (Author)
• Format: Book
• Published: Elsevier, 2019-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Dipeptidyl peptidase-4 (DPP-4) inhibitors not only improve impaired glucose tolerance in diabetes, but also have pleiotropic extra-pancreatic effects such as preconditioning effect for myocardial ischemia-reperfusion injury. Here, we investigated the anti-remodeling effects of linagliptin, a DPP-4 i...